autologous tumor DNA-transfected MRC-5 fibroblast vaccine

This experimental cancer vaccine, developed by Dr. Theresa Whiteside at the University of Pittsburgh Cancer Institute, utilizes a cell-based biologic modality to stimulate an immune response against non-small cell lung cancer (NSCLC). The vaccine is composed of semi-allogeneic human fetal lung fibroblasts (MRC-5 cell line) that have been transfected with genomic DNA extracted from the patient's own (autologous) tumor cells. By using semi-allogeneic fibroblasts as a vehicle, the vaccine aims to present a broad spectrum of patient-specific tumor antigens while providing additional immunostimulatory signals through MHC mismatch. The transfected fibroblasts are irradiated prior to administration to ensure safety while maintaining their ability to present antigens. This approach has been evaluated in Phase IB clinical trials to assess its safety and immunogenicity in patients with NSCLC.

Other names

semi-allogeneic human fibroblasts (MRC-5) transfected with DNAautologous tumor DNA-transfected fibroblast vaccinesemi-allogeneic human fibroblasts (MRC-5)-Theresa Whiteside, PhD-non-small cell lung cancer